Association of hepatitis C virus infection with serum iron status: Analysis of data from the third national health and nutrition examination survey

Clinical Infectious Diseases

Volumn 40, Issue 6, 2005, Pages 834-841

  Shan, Ying ^a   Lambrecht, Richard W ^a   Bonkovsky, Herbert L ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; IRON; TRANSFERRIN;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTICAL ERROR; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEALTH SURVEY; HEMOCHROMATOSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRON BLOOD LEVEL; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NUTRITION; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TRANSFERRIN BLOOD LEVEL; UNITED STATES;

ADOLESCENT; ADULT; CHILD; FEMALE; FERRITINS; HEPATITIS C; HUMANS; IRON; LIVER; MALE; MIDDLE AGED; PLATELET COUNT; PREVALENCE; TRANSFERRIN; UNITED STATES;

EID: 14944342277     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/428062     Document Type: Review

References (55)

1. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999; 31(Suppl 1):88-91.
2. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25:759-68.
3. Bonkovsky HL, Lambrecht RW. Iron-induced liver injury. Clin Liver Dis 2000; 4:409-29.
4. Bonkovsky HL. Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol 2002; 97:1-4.
5. Dickey W. Iron deficiency, gastric atrophy, and Helicobacter pylori. Dig Liver Dis 2002; 34:313-5.
6. Barton JC, Edwards CQ. Hemochromatosis: genetics, pathophysiology, diagnosis and treatment. Cambridge: Cambridge University Press, 2000.
7. Bonkovsky HL, Banner BF, Lambrecht RW, Rubin RB. Iron in liver diseases other than hemochromatosis. Semin Liver Dis 1996; 16:65-82.
8. Barton AL, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 1995; 103:419-24.
9. Fargion S, Fracanzani AL, Rossini A, et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol 2002; 97:1204-10.
10. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994; 20:410-5.
11. Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996; 91:1367-73.
12. Piperno A, Sampietro M, D'Alba R, et al. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996; 16:248-54.
13. Tsai NC, Zuckerman E, Han SH, Goad K, Redeker AG, Fong TL. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997; 92:1831-4.
14. Fontana RJ, Israel J, LeClair P, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000; 31:730-6.
15. DiBisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000; 32:135-8.
16. Sartori M, Andorno S, Rigamonti C, Boldorini R. Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig Liver Dis 2001; 33:157-62.
17. Yano M, Hayashi H, Wakusawa S, et al. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 2002; 97:133-7.
18. Shedlofsky SI. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question? Am J Gastroenterol 2002; 97:1093-6.
19. Weiss G, Wernerfelmayer G, Werner ER, Grunewald K, Wachter H, Hentze MW. Iron regulates nitric-oxide synthase activity by controlling nuclear transcription. J Exp Med 1994; 180:969-76.
20. Recalcati S, Pometta R, Levi S, Conte D, Cairo G. Response of monocyte iron regulatory protein activity to inflammation: abnormal behavior in genetic hemochromatosis. Blood 1998; 91:2565-72.
21. Weiss G, Umlauft F, Urbanek M, et al. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J Infect Dis 1999; 180:1452-8.
22. Mencacci A, Cenci E, Boelaert JR, et al. Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis 1997; 175:1467-76.
23. Pietrangelo A, Montosi G, Garuti C, et al. Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin. J Bioenerg Biomembr 2002; 34:67-79.
24. Bonkovsky HL, Troy N, McNeal K, et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 2002; 37:848-54.
25. Kakizaki S, Takagi H, Horiguchi N, et al. Iron enhances hepatitis C virus replication in cultured human hepatocytes. Liver 2000; 20:125-8.
26. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Series 1: programs and collection procedures. Vital Health Stat 1994; 32:1-407.
27. Gunter EW, McQuillan G. Quality control in planning and operating the laboratory component for the Third National Health and Nutrition Examination Survey. J Nutr 1990; 120(Suppl 11):1451-4.
28. Looker AC, Gunter EW, Johnson CL. Methods to assess iron status in various NHANES surveys. Nutr Rev 1995; 53:246-54.
29. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137:1-10.
30. Yano E, Tagawa K, Yamaoka K, Mori M. Test validity of periodic liver function tests in a population of Japanese male bank employees. J Clin Epidemiol 2001; 54:945-51.
31. Ruhl CE, Everhart JE. Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology 2003; 124:1821-9.
32. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114:311-8.
33. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96:2448-55.
34. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31:421-9.
35. Hayashi H, Wakusawa S, Takikawa T, Ikeda R, Yano M, Yoshioka K. Long-term effect of iron removal on chronic hepatitis C (abstract 345). Hepatology 1997; 26:215A.
36. Iwasa M, Kaito M, Ikoma J, et al. Dietary iron restriction improves aminotransferase levels in chronic hepatitis C patients. Hepatogastroenterology 2002; 49:529-31.
37. Rigamonti C, Andorno S, Maduli E, et al. Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. Eur J Clin Invest 2002; 32(Suppl 1):28-35.
38. Hofer H, Osterreicher C, Jessner W, et al. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 2004; 40:1018-22.
39. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002; 65:166-76.
40. Patrick L. Nonalcoholic fatty liver disease: relationship to insulin sensitivity and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine. Altern Med Rev 2002; 7:276-91.
41. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89:986-8.
42. Shiono Y, Hayashi H, Wakusawa S, et al. Body iron stores and iron restoration rate in Japanese patients with chronic hepatitis C as measured during therapeutic iron removal revealed neither increased body iron stores nor effects of C282Y and H63D mutations on iron indices. Nagoya J Med Sci 2001; 64:51-7.
43. Ioannou GN, Dominitz JA, Weiss NS, Heagerty PJ, Kowdley KV. Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology 2003; 37:795-801.
44. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000; 119:1385-96.
45. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kD) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39:1702-8.
46. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30:787-93.
47. Wurapa RK, Gordeuk VR, Brittenham GM, Khiyami A, Schechter GP, Edwards CQ. Primary iron overload in African Americans. Am J Med 1996; 101:9-18.
48. Moyo VM, Mandishona E, Hasstedt SJ, et al. Evidence of genetic transmission in African iron overload. Blood 1998; 91:1076-82.
49. Popkin BM, Siega-Riz AM, Haines PS. A comparison of dietary trends among racial and socioeconomic groups in the United States. N Engl J Med 1996; 335:716-20.
50. Polednak AP. Black-white differences in sentinel causes of death: counties in large metropolitan areas. J Urban Health 2000; 77:501-7.
51. Smith BC, Grove J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998; 27:1695-9.
52. Erhardt A, Maschner-Olberg A, Mellenthin C, et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003; 38:335-42.
53. Geier A, Reugels M, Weiskirchen R, et al. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. Liver International 2004; 24:285-94.
54. Eisenbach C, Gehrke SG, Stremmel W. Iron, the HFE gene, and hepatitis C. Clin Liver Dis 2004; 8:775-85.
55. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999; 116:127-34.